13F Holdings
中文EN

PYXS Pyxis Oncology, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1782223 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-4.8%
TTM EPS YoY28.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin97.1%
Operating margin-554.1%
Net margin-478.9%
FCF margin-358.7%
EBITDA margin-535.6%

Returns

ROE-62.8%
ROA-46.7%
ROIC (approx.)-65.0%
Asset turnover0.10x

Leverage & solvency

Liabilities / assets23.2%
Debt / equity0.00x
Current ratio7.49x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-11.9%
Payout ratio—
Capex / revenue1.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$13.86M$16.15M———
Cost of revenue$2.39M$475,000———
Gross profit$11.47M$15.67M———
R&D expense$73.70M$58.75M$49.59M$86.13M$51.05M
SG&A expense$22.19M$25.42M$32.61M$37.35M$18.66M
Operating income-$84.42M-$89.46M-$82.20M-$123.48M-$69.72M
Pretax income-$78.23M-$79.50M-$73.79M——
Income tax$1.39M-$2.16M———
Net income-$79.62M-$77.33M-$73.79M-$120.72M-$75.97M
EBITDA-$79.91M-$86.48M-$80.27M-$122.77M-$69.07M
EPS (basic)-1.28-1.32-1.85-3.65-8.95
EPS (diluted)-1.28-1.32-1.85-3.65-8.95
Weighted avg. shares (diluted)62.14M58.45M39.90M33.03M8.49M
Balance sheet
Cash & equivalents$15.42M$19.47M$9.66M$179.29M$274.74M
Short-term investments$51.44M$107.46M$109.63M——
Current assets$72.11M$132.44M$124.60M$186.61M$278.67M
PP&E, net$8.00M$9.90M$11.87M$11.16M$1.01M
Intangibles$0$2.60M$24.31M——
Total assets$91.52M$157.18M$173.73M$211.38M$280.02M
Current liabilities$21.13M$17.68M$25.76M$31.63M$18.71M
Total liabilities$38.11M$36.43M$48.02M$50.55M$18.71M
Shareholders' equity$53.41M$120.75M$125.70M$160.82M$261.31M
Shares outstanding62.69M59.97M44.75M34.96M32.22M
Cash flow statement
Operating cash flow-$63.50M-$57.67M-$70.71M-$89.33M-$35.33M
Capital expenditure$9,000$237,000$6.73M$6.40M$540,000
Free cash flow-$63.51M-$57.91M-$77.44M-$95.73M-$35.87M
Investing cash flow$58.86M$8.15M-$104.85M-$6.40M-$590,000
Financing cash flow$594,000$59.33M$5.93M$183,000$304.04M
Depreciation & amortization$4.51M$2.98M$1.93M$709,000$647,000
Stock-based compensation$11.80M$12.95M$16.95M$15.76M$6.44M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.